Driving their expertise in genomics-based health and disease testing, Genetic Technologies (ASX: GTG) has partnered CancerIQ, a widely used platform that assists healthcare providers identify high-risk patients and prioritise preventive cancer screenings. CancerIQ has become a resource for healthcare institutions and clinics by simplifying the identification of individuals at risk for hereditary cancers. By embedding
Read More
A benchmarking study comparing ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV)’s blood test against ultrasound has been published in the scientific journal “Cancers” with positive outcomes. The study found that Cleo’s initial test for the surgical triage market significantly outperforms the current clinical workflows that use Cancer Antigen 125 (CA125) and ultrasound to predict
Read More
In 2023, pancreatic cancer transitioned from being a rare form to a common cancer in Australia—a troublesome statistic, seeing as it has very low survival rates of about 12%. The symptoms of pancreatic cancer are in advanced stages, making it difficult to treat.
Read More
In 2020, the Department of Health and Aged Care revealed that approximately 2,000 Australians were diagnosed with brain cancer. New cases of brain cancer are increasing every year and Glioblastoma, the most common, complex, treatment-resistant, and deadliest type of brain cancer, accounts for 45% of all malignant brain tumours. On a global scale, it is
Read More
Offering some relief for people suffering from prostate cancer, Starpharma (ASX: SPL) might be on the verge of a breakthrough as it announced that its drug DEP® cabazitaxel has shown promising anti-tumour activity data at the European Society of Medical Oncology (ESMO) Congress in Paris, France. The new data from its phase 2 trial reveals
Read More
CF33-hNIS-antiPDL1. *moves mouse to x button to close tab* “But wait!” your writer screams from the page, “I promise it’s interesting!” Whilst I may not have the teaching prowess of Ms Frizzle, I implore you to stick around, because Imugene’s (ASX: IMU) immuno-oncology stuff is really interesting once you wrap your head around it. The
Read More